MENU
+Compare
ANAB
Stock ticker: NASDAQ
AS OF
Sep 12 closing price
Price
$23.40
Change
+$0.20 (+0.86%)
Capitalization
654.57M

ANAB AnaptysBio Forecast, Technical & Fundamental Analysis

AnaptysBio Inc is a clinical-stage biotechnology company... Show more

Industry: #Biotechnology
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ANAB with price predictions
Sep 12, 2025

Momentum Indicator for ANAB turns positive, indicating new upward trend

ANAB saw its Momentum Indicator move above the 0 level on August 28, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned positive. In of the 100 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ANAB's RSI Oscillator exited the oversold zone, of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ANAB just turned positive on August 27, 2025. Looking at past instances where ANAB's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

ANAB moved above its 50-day moving average on September 11, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for ANAB crossed bearishly below the 50-day moving average on August 08, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ANAB broke above its upper Bollinger Band on September 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.301) is normal, around the industry mean (20.524). P/E Ratio (0.000) is within average values for comparable stocks, (53.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.172). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (5.596) is also within normal values, averaging (337.274).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ANAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ANAB is expected to report earnings to rise 5.22% to -140 cents per share on November 11

AnaptysBio ANAB Stock Earnings Reports
Q3'25
Est.
$-1.41
Q2'25
Beat
by $0.18
Q1'25
Beat
by $0.02
Q4'24
Beat
by $0.90
Q3'24
Beat
by $0.56
The last earnings report on August 07 showed earnings per share of -134 cents, beating the estimate of -151 cents. With 472.66K shares outstanding, the current market capitalization sits at 654.57M.
A.I. Advisor
published General Information

General Information

a provider of therapeutic antibodies for inflammation and immuno-oncology

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10770 Wateridge Circle
Phone
+1 858 362-6295
Employees
117
Web
https://www.anaptysbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BIAGX17.72N/A
N/A
Brown Advisory Growth Equity Inv
GAUAX5.24N/A
N/A
Gabelli Utilities A
JLCFX76.22N/A
N/A
JHancock Fundamental Large Cap Core R4
CSMDX16.17N/A
N/A
Copeland SMID Cap Dividend Growth I
RFIMX7.56N/A
N/A
Ranger Micro Cap Institutional

ANAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with QTTB. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
+0.86%
QTTB - ANAB
39%
Loosely correlated
+2.66%
CLRB - ANAB
39%
Loosely correlated
-3.79%
AMRN - ANAB
38%
Loosely correlated
+0.27%
ADCT - ANAB
37%
Loosely correlated
-0.60%
SPRY - ANAB
36%
Loosely correlated
-1.18%
More